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2ABBREVATION
NVD - Neovascularistion of disc
NVE - Neovascularisation elsewhere
SLE - Systemic Lupus Erythematosus
PAN - Polyarteritis Nodosa
ESR - Erythrocyte Sedimentation Rate
CRP - C-Reactive protein
HLA - Human leukocyte antigen
CMV - Cytomegalovirus
AIDS - Acquired immunodeficiency syndrome
ACE - Angiotensin converting enzyme
TORCH- Toxoplasmosis, Rubella, Cytomegalovius,
Herpes virus
3INTRODUCTION
Retinal vasculitis is considered to be Type 3 hypersensitivity
reaction of retinal vasculature affecting veins, arteries or both. The
pathological evidence indicates that the basic pathology is perivascular.
The disease is characterized by occurrence of hemorrhages in the retina,
vitreous, or with recurrence of haemorrhages. The disease can progress
and lead to fibovascular membrane and tractional retinal detachment,
complicated cataract and secondary glaucoma.
The first attempt to discuss in detail the clinical syndrome of
recurrent  haemorhages was made by HENRY EALES (1880-82).1
PERLS(1873) and ANGELUCCI(1878) studied the histological
appearance of periphlebitis.
WADSWORTH (1887) was the first to describe the clinical picture
of perivasculitis.
AXENFELD and STOCK (1909-11) drew attention to the
etiological significance of tuberculosis.
4CLASSIFICATION OF RETINAL VASCULITIS
DUKE ELDER’S CLASSIFICATION1
1. Vasculitis secondary to uveitis
2. Vasculitis secondary to systemic disease
3. Apparently primary vasculitis
COGAN’S CLASSIFICATION2
1. Mild papillophlebitis,
2. Moderate vasculitis-bilateral-arterioles and/or veins affected,
3. Severe vasculitis – arterioles involved more than veins.
RECENT CLASSIFICATION3
1. Primary vasculitis,
2. Vasculitis secondary to systemic diseases,
3. Vasculitis secondary to ocular disease.
5CLINICAL CHARACTERISTICS OF RETINAL VASCULITIS
SYMPTOMS3
Painless decrease/marked loss of vision,
Floaters,
Large areas of scotomata,
Asymptomatic if the lesions are in the peripheral retina.
SIGNS3
Sheathing of vessels,
Obliteration and perivascular edema,
Occlusive retinopathy characterized by large areas of capillary drop
outs,
Vascular architectural alteration manifesting as
arteriolar/venule anastamosis and crossing of vessels
over horizontal raphe,
Recurrent vitreous hemorrhage,
Cystoid macular edema.
6PRIMARY VASCULITIS
Eales Disease,
Idiopathic Retinal Vasculitis, Aneurysms And Neuroretinitis
(IRVAN)
Frosted Branch Angiitis,
Scleritis.
EALES DISEASES
Eales disease is a idiopathic bilateral, asymmetric condition that
manifest as an obliterative perivasculitis4 (particularly involving the
venous side) affecting retina in multiple quadrant, starting at or anterior to
the equator and progressing posteriorly.
The disease is named after Henry Eales, an ophthalmologist in
1880, he described as a syndrome of recurrent vitreous hemorrhage in
young men with epistaxis and constipation.5 He termed the condition as
primary recurrent retinal hemorrhage. With the advent of ophthalmoscope
he was able to document abnormal retinal veins and areas in the
peripheral retina that were free of capillaries.
In 1887, Wadsworth described the association of inflammation and
neovascularization with the disease.
7Eales disease affects healthy young adults with average age of
onset at 15-45 years, with male predominance6 and poor socioeconomic
class.
CLINICAL FEATURES
Eales disease is an idiopathic, peripheral, bilateral, retinal vasculitis
resulting in peripheral non-perfusion and neovascularization in healthy
male population.
Presenting symptoms in most patients are floaters and painless
diminution of vision.
Anterior segment is normal in patients with Eales, presence of cells
and flare in these patient is the first indicator of development of rubeosis
iridis.
Clinically the various features of Eales’disease can be divided into
signs of Inflammation, signs of Ischemia, signs of Neovascularization and
its sequelae.7
8FIG-1 BILATERAL EALES
9INFLAMMATION
Ocular inflammation is the commonest manifestation of Eales
disease. Vascular sheathing occurs in 80% of patients with involvement
ranging from thin, contiuous white lines, to thick exudates which are
segmental.8
Keratic precipitates, anterior chamber cells and flare, vitreous cells.
Cystoid macular edema occurs in eyes with extensive sheathing. Fundus
fluorescein angiography demonstrates hyperfluorescence in the areas of
vascular sheathing and staining in the active stage of disease.(Figure 2,3,4
&5)
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EALES DISEASE
FIGURE-2-STAGE OF INFLAMMATION
FIGURE-3-SHEATHING OF VESSELS
11
FIGURE-4-SHEATHING WITH HAEMORRHAGE
FUNDUS FLUORESCEIN ANGIOGRAPHY
FIGURE-5-STAINING OF VESSELS
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NONPERFUSION OR ISCHEMIA
Peripheral retinal nonperfusion is present in all the patients, which
extends from small to massive areas.
Intraretinal hemorrhages appears first in the affected area, followed
by increase in vascular tortuosity with collateral formation around the
occluded vessels, with microaneurysm, arteriovenous shunt and venous
beading seen at the junction.9
Patients with Eales disease experience branch retinal vein
occlusion, can be single or multiple associated with peripheral retinal
involvement not respecting the horizontal midline.(Figure-6,7)
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STAGE OF ISCHEMIA
Figure-6 AREAS OF CAPILLARY NON-PERFUSION
FIGURE-7
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NEOVASCULARIZATION
The retinal nonperfusion leads to eventual development of new
vessels. Neovascularisation occurs over disc, retina or iris. These
abnormal blood vessels  frequently bleed and are major cause of visual
loss.
About 80% of the patient present with vitreous hemorrhage due to
neovascularization. New vessels occur in the intraretinal, preretinal and
intravitreal locations. In advanced disease due to global ischemia NVD
develops.
The commonest sequelae of neovascularization is vitreous
hemorrhage which can lead to tractional retinal detachment. Since in
Eales the posterior pole is not involved, visual loss is minimal. But as the
disease progresses tear develops in the retina due to traction, producing
combined detachment.9,10(Figure 8,9)
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Figure-8 STAGE OF NEOVASCULARISATION
Figure-9 FFA-MID-PHASE SHOWING INTENSE LEAKAGE
SUGGESTIVE OF NEW VESSEL
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CENTRAL EALES
The prevalence of central Eales is 6%. This presents as a
papillophlebitis or non-ischemic central retinal vein occlusion. Prognosis
is good in this case.9
CLASSIFICATION OF EALES
Classification is based on the evolution and progress of the disease.
The classification divided the disease into four stages
Stage 1
Mild periphlebitis of peripheral retinal capillaries
Stage 2
Wide spread periphlebitis of the venous system
Stage 3
New vessel formation and vitreous hemorrhage
Stage 4
End result of multiple hemorrhages –Retinitis proliferans.
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NEW SYSTEM OF CLASSIFICATION
This new system of classification divides the disease into central
and peripheral, and peripheral type is further subdivided as
STAGE 1a
Periphlebitis of small caliber vessels with superficial retinal hemorrhages.
Stage 1b
Periphlebitis of large caliber vessels with superficial hemorrhages.
Stage 2a
Areas of capillary non-perfusion.
Stage 2b
Neovascularization of disc and elsewhere.
Stage 3a
Fibrovascular Proliferation
Stage 3b
Vitreous hemorrhage
STAGE -4a
Traction Or Combined Retinal detachment
Stage-4b
Rubeosis iridis, Neovascular glaucoma, cataract and optic atrophy.9
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ETIOPATHOLOGY
Multiple pathological, immunological, molecular biological and
biochemical studies have indicated the role of HLA antigen,
autoimmunity, mycobacterial genome and oxidative stress mechanism in
the pathogenesis of vasculitis.11
Higher phenotypic association of HLA B5, DR1 and DR4 was seen
in patients with retinal vasculitis.12
Polymerase chain reaction using IS 6110 primers was done to
detect the bacterial genome in vitreous fluid, Epiretinal membrane and
was statistically found in Eales patients.
Biochemical studies show that the protein carbonyl group content
increases with severity of Eales disease, indicating the role of oxidative
stress in Eales disease.13
DIFFERENTIAL  DIAGNOSIS
Eales disease has to be differentiated from other causes of Retinal
vasculitis or Retinitis.
Cytomegalovirus Retinitis
Behcet’s Disease
Sarcoidosis
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Leukemia
Syphilis
Tuberculosis
Multiple sclerosis
Parsplanitis
Toxoplasma
Toxocara
Systemic lupus erythematosus
Lyme borreliosis
SYSTEMIC ASSOCIATION OF EALES14
Acute/subacute myelopathy
Multifocal white matter abnormality
Ischemic or infarction of brain and manifests as, focal neurological signs
and demyelination
Abnormalities in the peripheral vestibular system
Bilateral sensorineural hearing loss
Hemiplegia and paraparesis
Internuclear ophthalmoplegia
Psychosis
20
MANAGEMENT
MEDICAL TREATMENT
Corticosteroids are given to the patients systemically 2mg/kg
during the phase of inflammation and tapered over a period of 6-8 weeks.
Subtenon injections of triamcinalone are administered in the dose
of 0.5-1ml(40mg/ml).
Antimetabolite, low dose oral methotrexate (12.5mg/wk) for 12
weeks are indicated for one eyed and patients with central Eales disease.
Patients with excessive exudative sheathing and nodule formation,
strongly positive mantoux were started on antitubercular drugs, Isoniazid
(300mg) and Rifampicin (450mg) for a period of 9 months.14
LASER TEATMENT
Retinal laser treatment is performed for the regression of existing
new vessels by photocoagulating the areas of ischemia. Panretinal
photocoagulation performed in the presence of NVD or when extensive
areas of ischemia exists.
Photocoagulation is done to the extreme periphery using laser
indirect ophthalmoscope.
Retinal anchoring treatment, in this procedure laser is applied to the
base of the fibrovascular traction to prevent combined detachment.15
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PARS PLANA VITRECTOMY
INDICATIONS
Media opacities
Fibrous and fibrovascular areas of adhesion of the posterios vitreous
Nonresolving vitreous hemorrhage (>6-8 weeks)
Combined retinal detachment
Tractional detachment threatening the macula 16
IDIOPATHIC RETINAL VASCULITIS,
ANEURYSMS, NEURORETINITIS (IRVAN syndrome)
IRVAN is a disease of young age with features of multiple saccular
and fusiform aneurysm involving large arterioles combined with
peripheral vascular non-perfusion and uveitis, neuroretinitis, retinal
neovascularization, optic nerve head swelling and anterior uveitis
associated with this disorder.
The disease has been seen in pregnant women in a hypercoagulable
state and peripheral venule and arteriolar occlusion is noted
Retinal laser photocoagulation performed as early as possible to the
areas of non-perfusion.17
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FROSTED BRANCH ANGIITIS
As per Walker et al, Frosted branch angiitis is a florid translucent
retinal perivascular sheathing. It is generally noted in young individuals.
There is severe drop in visual acuity during acute period. Both arteries
and veins can be involved mostly venules are affected more. Most of the
cases are bilateral, there is no gender predilection.
Frosted branch angiitis may be
Idiopathic
CMV retinitis
Tuberculosis
Syphilis
Herpes simplex type 2
Aseptic meningitis.
Lymphoma
Leukemia
Sarcoidosis
Multiple sclerosis
Pars planitis
Systemic lupus erythematosis
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MASUDA and COWORKERS reported a patient with frosted
branch angiitis with multiple placoid lesion suggestive of occlusion of
choriocapillaries.
Neovascularisation of disc and retina were reported in some patient
in whom retinal ischemia was associated.
Steroids and laser photocoagulation to ischemic areas had good
visual outcome.11
SCLERITIS
The vasculature near the scleritis is integrally involved in
inflammatory and pathological process. The inflammatory reaction in
anterior scleritis with spill over leading to anterior or intermediate uveitis.
Posterior scleritis patients present with severe ocular pain with
minimal anterior segment changes, minimal vitreous changes, choroidal
folds and retinal thickening. Ultrasound examination helps in the
diagnosis. Corticosteroid therapy helps to control the disease. But
recurrences do occur. Whether Posterior scleritis is associated with a
systemic disorder must be ruled out.18
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OCULAR VASCULITIS DUE TO SYSTEMIC DISEASES
Behcet’s Disease
Sarcoidosis
Systemic Lupus Erythematosus
Postvaccination
Multiple Sclerosis
Wegener’s Granulomatosis
Takayasu’s Disease
Buerger’s Disease
Polyarteritis Nodosa
Polymyositis
Dermatomyositis
Whipple’sdisease
Crohn’s Disease
Sjogren’s A Antigen
Kikuchi-Fujimoto Disease
Susac’s Syndrome
SYSTEMIC DISORDER
Retinal vasculitis is associated with collagen vascular group of
disorder. Patients usually present with malaise, weight loss, arthritis, fever
and rash. Also present with mononeuritis multiplex, a disease which
progress to affect multiple nerve roots especially in the lower extremities.
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SARCOIDOSIS
Sarcoidosis causes myriad of ocular manifestations including
severe involvement of retinal vasculature. It affects commonly the age
group less than 40 yrs.
Unknown antigen or abnormal defense mechanism triggered by
various insults responsible for T-cell activation is the prime pathogenesis
in sarcoidosis. Increased levels of serum VEGF has been observed in
sarcoidosis.
PATHOLOGY
Histopathology findings are multiple non-caseating, epitheloid
granulomas. The centre of granulomas consist of histiocytes, epitheloid
cells and multinucleated giant cells that may contain intracytoplasmic
inclusions such as asteroid and schaumann bodies.19
OCULAR SARCOIDOSIS
It’s the third common manifestation of sarcoidosis preceded by
pulmonary disease and hilar lymphadenopathy. Ocular disease may be the
presenting feature in 9% cases. Two peaks in age incidence for ocular
sarcoid include 20-30yrs and 50-60yrs.
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Sarcoid related uveitis occur in five ways
Acute anterior uveitis
Chronic anterior uveitis
Intermediate uveitis.
Posterior uveitis
Panuveitis
Retinal vasculitis constitute one of the cardinal features of posterior
segment involvement. It is characterized by perivenous sheathing in the
equatorial retina, which is usally segmental. Vasculitis may result in
leakage or occlusion of the lumen of vein leading to ischemia, exudation
and edema. Neovascularization is due to ischemia resulting from
inflammation and vein occlusion.19(Fig-10,11)
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FIG-10SARCOIDOSIS
FIG-11 CANDLE WAX DRIPPING
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VASCULITIS IN MULTIPLE SCLEROSIS
Multiple sclerosis is a chronic inflammatory demyelinating
disease of central nervous system mostly affecting young adults. ocular
manifestations include Opticneuritis, Extraocularmuscle disturbance and
intraocular inflammation.
It was reported by Rucker that 20% of patient with Multiple
sclerosis have vascular sheathing as their association.20
Retinal vasculitis in multiple sclerosis patient is exclusively
periphlebitis, 21Retinal venous sheathing. It encompasses both the active
and chronic form. The chronic form of sheathing appears typically as
dense white strips over several branches of vascular tree.
Activity of periphlebitis is not correlated with Optic neuritis,
systemic exacerbation or severity of disease. It can lead to occlusive
vasculitis with subsequent formation of neovascularisation.22
BEHCET’S DISEASE
Ocular Behcet’s is characterized by nongranulomatous uveitis with
retinal vasculitis. The reported frequency of ocular manifestation is
83-95% in males and 67-73% in females.
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Retinal vasculitis is of occlusive nature characterized by retinal
edema, yellowish white exudates and hemorrhages. Behcet’s disease is
the only systemic vasculitis that affects both arteries and veins and this
feature is pathognomic of Behcet’s vasculitis. Occlusive nature of
vasculitis will lead to neovascularistion.23
NECROTIZING VASCULITIS
Disorder with pathogenesis being linked to antineutrophilic
cytoplasmic antibodies plus environmental and genetic factors.
POLYARTERITS NODOSA AND MICROSCOPIC POLYANGIITIS
SYSTEMIC COURSE OF PAN
Neuropathy
Nephropathy
Cutaneous ulcers
Gastrointestinal thrombosis and infarction
Musculoskeletal pain
Coronary arteritis
CNS involvement
OCULAR MANIFESTATION OF PAN
Microangiopathy with cotton wool patches
Serous Retinal Detachment
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Retinal Vasculitis
Artery occlusion
Ischemic Optic Neuropathy.24
CHURG STRAUSS SYNDROME
ACR criteria for diagnosis of Churg Strauss Syndrome
Asthma, adult onset
Eosinopilia >10% in the blood
Sinusitis
Pulmonary infiltrates
Neuropathy
Biopsy with vasculitis and Eosinophils
OCULAR MANIFESTATION
Retinal vascular disorders like
Ischemic Optic Neuropathy
CRAO
BRAO
CRVO
Retinal Vasculitis
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WEGENER GRANULOMATOSIS
It’s a triad of Systemic necrotizing vasculitis(87%), necrotizing
granulomatous involvement of respiratory tract and necrotizing
glomerulonephritis.
ACR criteria for diagnosis
2 of 4
Inflammation in the nose and mouth
Abnormal urinary sediment
Abnormal chest x-ray
Granulomatous inflammation of arteries
OCULAR MANIFESTATION
Orbit (13%)
Eyelid and Nasolacrimal duct (13%)
Episcleritis and Scleritis (11%)
Keratitis (8%)
Optic neuropathy (6%)
Conjunctivitis (4%)
Retinal vasculopathy (5%)(Figure-12,13)
Uveitis (3%).24
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Fig-12PERIARTERITIS AND PERIPHLEBITIS IN
WEGENERS GRANULOMATOSIS
FIG-13
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SYSTEMIC LUPUS ERYTHEMATOSUS
It’s an immune complex disorder, which affects the eye with severe
intraocular complication .Ocular involvement is common in the form of
dryness.
In 7.5% of the patients with SLE retinal vasculopathy is mostly as
microangiopathic changes with cotton wool spots.
Cotton wool spots and retinal hemorrhages correlate with disease
activity and are of negative prognostic sign.
SLE patients with anti-phospholipid syndrome have increased risk
for retinal vasoocclusive disease.
The pathogenesis of SLE are complex and partially understood,
include triggering agent such as infection might lead to activation of
autoreactive T and B cells
Treatment of microangiopathic changes should be chosen in the
context of systemic disease. Remission is induced with intravenous
cyclophosphamide and maintained with other immunosuppresants like
azathioprine, Mycophenolate mofetil and Rituximab are emerging
therapies for SLE.(FIG-14,15 &16)
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FIG-14 SLE PERIARTERITIS-OD
FIG-15 SLE PERIARTERITIS –OS
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FIG-16 VASCULITIS DUE TO SYSTEMIC LUPUS
ERYTHEMATOSUS
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RETINAL VASCULITIS DUE TO INFECTIOUS DISORDER
Syphilis
Hepatitis C
Chickenpox
Toxoplasmosis
Toxocariasis
Coccidiomycosis
Tuberculosis (Fig-17)
Cytomegalovirus infection (Fig-18,19)
Herpes simplex
Herpes zoster
Acute retinal necrosis
Candidiasis
Leptospiosis
Rickettsia
Brucellosis
Amoebiasis
Mononucleosis
Lyme’s disease
Hepatitis B
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FIG-17 POST-INFECTIVE VASCULITIS
FIG-18 CMV RETINITIS
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FIG-19 CMV RETINITIS
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VASCULITIS DUE TO OCULAR DISEASES
Pars planitis
Choroiditis
Posterior uveitis
Behcet’s retina sine systemic disease
Birdshot retinochoroidopathy
Acute multifocal hemorrhagic retinal vasculitis25
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DIAGNOSTIC STUDIES IN PATIENTS WITH
RETINAL VASCULITIS
LABORATORY TESTS
Complete blood count with differential count
Erythrocyte sedimentation rate
C-reactive protein
Serum chemistry panel with tests for retinal and liver function
Bloodsugar
Urinanalysis
VDRL and FTA-ABS
Tuberculin skin testing
TORCH Screening
Serum ACE
Rheumatoid factor
Antinuclear antibody
Antineutrophil cytoplasmic antibody
Antiphospholipid antibody
Serum protein electrophoresis
Serum cryoglobulins
Human  leukocyte antigen testing
Vitreous biopsy
CSF Cytology and cell count
41
IMAGING
Fluorescein angiography
Optical Coherence Tomography
Ultrasonography
Chest X-ray
Magnetic Resonance Imaging
Gallium scan
Sacroiliac joint x-ray.26
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TREATMENT MODALITIES
ANTI-INFLAMMATORY
CORTICOSTEROIDS
Systemic route (oral or intravenous administration)
Sub-tenon’s injection
Intravitreal  Triamcinalone
Intravitreal implants
IMMUNOMODULATORS
Alkylating agents
Anti-metabolite
T-lympocytes modulators
Biological response modifiers.
LASER THERAPHY
Pan-retinal photocoagulation
SURGICAL THERAPHY
Pars plana vitrectomy
CORTICOSTEROIDS
INDICATIONS
Treatment of active inflammation in the eye
Prevention and treatment of complication
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Reduction of inflammatory infiltrates of retina, choroid or optic nerve.
SYSTEMIC THERAPY
Prednisalone is commonly used drug 1-2mg/kg/day of oral
prednisalone given for period of 6-8wks and gradually tapered.
In cases of severe non-infectious posterior uveitis and panuveitis
pulse dose of steroids 1gm/day infused over 1 hour administered for 3
days followed by gradual taper of oral steroids.
Complications of oral steroids
FLUIDS,ELECTROLYTES
Sodium retention, potassium loss
Fluid retention
Hypokalemic alkalosis
Hyperosmolar coma
MUSCULOSKELETAL
Muscle weakness
Steroid myopathy
Osteoporosis
Aseptic necrosis of femoral and humeral head
Tendon rupture
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GASTROINTESTINAL
Nausea
Increased appetite
Peptic ulcer
Perforation of small and large bowel
Pancreatitis
DERMATOLOGIC
Poor wound healing
Easy brusiability
NEUROLOGICAL
Convulsion
Headache
Hyperexcitability
Moodiness
Psychosis
ENDOCRINE
Menstrual irregularities
Cushingoid state
Suppression of adrenocortical pituitary axis
Diabetes
45
OPHTHALMIC
Cataract
Glaucoma
Central serous retinopathy
Activation of herpes
OTHERS
Weight gain
Thromboembolism
SUB-TENON INJECTION
INDICATIONS
Posterior uveitis
Active stage of Retinal vasculitis
Non-complaint
Poor response to topical /systemic administration
METHOD OF INJECTION
Under topical anesthesia, using 25 gauge, 5/8 inch needle injection
given in the superotemporal or inferotemporal quadrant.
COMPLICATION
Upperlid ptosis
Globe perforation
Periorbital hemorrhage.
Glaucoma
Cataract.
Newer approach of local steroid injection include Trans Tenon
steroid injection.27
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PART TWO
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AIM OF THE STUDY
PRIMARY OBJECTIVE
? To classify the  RETINAL  VASCULITIS
? Compare the efficacy of Posterior sub tenon steroids and oral
steroids in patients with active vasculitis.
? To assess the final visual outcome  in the above groups after
complete treatment with (Immunosuppresant/laser as per
indication.)
SECONDARY OBJECTIVE
? To  determine   epidemiological  factors(age/sex), mode of
presentation
48
MATERIALS AND METHODS
This study was conducted in Regional Institute of Ophthalmology
and Government Ophthalmic Hospital, Egmore, Chennai from November
2009 to November 2011 for a period of 2 years.Its a single blind
randomised prospective and retrospective interventional clinical study.
INCLUSION CRITERIA:
All   cases   of    retinal   vasculitis    associated   with   ocular  or
systemic disease Criteria  for  diagnosis  of  retinal   vasculitis
One  of  following
1. Sheathing,
2. Para-vascular  edema,
3. Peri-vascular  inflammation,
4. Staining  of  vessel  wall in  FFA.
EXCLUSION CRITERIA:
1. Patients with contraindication for steroids,
2. Patient with scleral necrosis,
3. Patient with history of glaucoma,
SCREENING PROCEDURE
1. History,
2. Visual  acuity,
3. Intra-ocular  pressure,
49
4. Slit lamp examination,
5. Fundus examination with90D & IDO,
6. FFA ,
7. complete hemogram,ESR,blood and urine sugar,mantoux,
8. VDRL,ELISA  for  HIV,
9. serum ace,chest x-ray,
10. anti-nuclear antibody,RF,anti-DNA,C-reactive protein,
11. TORCH titre
12. c-ANCA/p-ANCA
DATA COLLECTION AND METHODS
All new and review cases diagnosed  as retinal  vasculitis were
subjected to above mentioned investigations  and  disease entity  was
classified  based  on the results of detailed evaluation.Total study
population included 50 patients.Of which 24 patients were classified as
primary vasculitis assigned for intervention study as Subgroups by
randomization.
? Patients with primary vasculitis with acute disease were  randomly
divided  into  two subgroups
? Subgroup 1 treated with oral steroids(1mg/kg/day) for a period of 8
weeks. .
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? Subgroup 2 with posterior sub-tenon steroids(20mg/0.5ml) given 2
wks once for 8 weeks
? Best corrected visual acuity treatment (snellen’s chart) .  Media
clarity using indirect ophthalmoscope, Fundus fluorescein
angiography if hemorrhages and media view was possible was
perfomed every week upto 8 weeks period
? Immunosuppressants (Azathioprine 2mg/kg/day) planned for
resistant cases (not responding to steroids treatment for period of 8
weeks )in the above two groups,
? Patient  treated with laser therapy pan retinal photocoagulation  for
those associated with neovascularistaion and extensive capillary
non -perfusion
? Follow up was done every week upto  8th , 12th and 16th weeks of
treatment .Results analysed at end of 16th week.
Assessment of parameters during follow up visits
1. Best corrected visual acuity before & after treatment (snellen’s
chart) .
2. Media clarity using indirect ophthalmoscope
3 Fundus fluorescein angiography if hemorrhages and media view
was possible
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AGE
OBSERVATION AND ANALYSIS
1. AGE DISTRIBUTION
TABLE-1
Age Group (Yrs) No. of Cases Percentage
10-20 2 10%
21 – 30 18 36%
31 – 40 20 40%
41 – 50 6 12%
>50 4 8%
Incidence of Retinal vasculitis is more in the age group of 31-40 years of age
(40%) followed by age group of 21 to 30 (36%).
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2. SEX DISTRIBUTION
TABLE-2
Sex No. of Cases Percentage
Male 43 86%
Female 7 14%
In our study, males were predominantly affected (86%).All Eales
patient were Male. In patients with  systemic disease 5 patient among the
15 were female and remaining 10 were male. All 10 patients with ocular
disease  were male.
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VASCULITIS
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3. CLASSIFICATION OF RETINAL VASCULITIS
TABLE-3
DISEASE NO PERCENTAGE
PRIMARY
RETINAL
VASCULITIS
25 50%
VASCULITIS
SECONDARY  TO
OCULAR DISEASE
10 20%
VASCULITIS
SECONDARY TO
SYSTEMIC
DISEASE
15 30%
In our study primary vasculitis was predominant, this was followed
by vasculitis secondary to systemic disease followed by vasculitis due to
ocular disease.
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4. LATERALITY
TABLE-4
LATERALITY
PRIMARY
VASCULITIS
SEC.TO
SYSTEMIC
DISEASE
SEC.TO
OCULAR
DISEASE
RIGHT EYE 6(24%) 2(13.33%) 3(30%)
LEFT EYE 4(16%) 3(20%) 2(20%)
BOTH EYE 15(60%) 10(66.66%) 5(50%)
In our study patients with eales  and vasculitis due to systemic
disease had predominant bilateral involvement.Patient with ocular disease
had equal unilateral and bilateral involvement.
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PERCENTAGE
INSIDIOUS
ACUTE
5. MODE OF PRESENTATION
TABLE-5
MODE OF
PRESENTATION NO PERCENTAGE
ACUTE 15 30%
CHRONIC 35 70%
Acute onset of visual loss was common in patients with Eales
disease due to vitreous hemorrhage
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6. PRESENTING COMPLAINTS
.
PRESENTING COMPLAINTS NO PERCENTAGE
SUDDEN LOSS OF VISION 15 30%
BLURRING OF VISION WITH
FLOATERS
20 40%
FLOATERS 15 30%
Blurring of vision was the predominant symptom and was
associated with floaters. Sudden loss of vision was seen in patients with
Eales with vitreous hemorrhage.
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7. CLINICAL SIGNS
TABLE-7
CLINICAL SIGNS PRIMARYVASCULITIS
SEC.TO
SYSTEMIC
DISORDERS
SEC.TO
OCULAR
DISORDERS
Sheathing of vessels
with staining and vitritis
25 EYES
(62.50%) 5 EYES (20%)
Vein occulsion 16 EYES (64%) 2 EYES (13.33%)
Neovascularisation 0
Vitreous hemorrhage 15 EYES(37.5%)
Tractional retinal
detachment 4 EYES (16%0
Sheathing with
exudation and vitritis
13 EYES
(86.66%)
Sheathing of vessels with vitritis and staining was seen in all
patients with acute disease due to Eales and ocular disease like posterior
uveitis.Vitreous hemorrhage and Neovascularisation was present in
patients with Eales disease.Vein occlusion present in patients with
systemic disease.Tractional Retinal Detachment was noted in 2 patients
with AIDS.
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8. BEST CORRECTED VISUAL ACUITY
TABLE-8
VISUAL
ACUITY
PRIMARY
VASCULITIS
SEC.TO
SSTEMIC
DISEASE
SEC.TO
OCULAR
DISEASE
6/6-6/18 20 EYES (50%)
6/24-6/60 5 EYES(12.5%)
5 EYES
(20%) 5 EYES (33.33%)
<6/60 15 EYES(37.5%)
20 EYES
(80%) 10 EYES (66.66%)
Visual acuity of <6/60 was seen in patients with vitreous
hemorrhage (among Eales patient),with AIDS (among patients with
vasculitis due to systemic disease), In other patient with systemic disease
visual acuity ranged from 6/24-6/60 .6/6-6/18 was noted in patients with
Eales .
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MANTOUX  RESPONSE  IN PATIENT WITH EALES
Of  the 25 cases of Eales 5 cases had mantoux positivity,of these
patient screened for pulmonary tuberculosis one patient was positive for
pulmonary tuberculosis and was excluded from the intervention
TREATMENT
24  Cases (24 eyes with active inflammation) of Eales  patient
randomly divided into 2 Subgroups.
Subgroup1 subjected to systemic steroids of 1mg / kg / day for
8week,
Subgroup2 subjected to posterior sub-tenons 20mg / 0.5ml once
every 2 wks for 8weeks,
Both groups observed at  4week and 8 week,12th week and 16th
week.
Parameters  observed  on follow up
Visual acuity
Vitritis grading (media clarity)
Fundus fluorescein angiography.
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9. MEDIA CLARITY (VITRITIS) AT INITIATION OF
TREATMENT
TABLE-9
MEDIA CLARITY
VITRITIS(GRADE)
SUB-GROUP I
ORAL
SUB-GROUP-II
POST.SUB-TENON
0 0 0
I 8(66.67%) 8(66.67%)
II 4(25%) 4(25%)
III 0 0
66.667% was had grade 1 vitritis at initiation of  treatment in both
the sub group.
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10. VISUAL ACUITY AT INITIATION OF TREATMENT
TABLE-10
BCVA
SUB-GROUP- I
ORAL
SUB-GROUP-II
SUB-TENON
6/9NIP 4(33.33%) 4(33.33%)
6/12-6/18 8(66.67%) 8(66.67%)
<6/18 0 0
Best corrected visual acuity was 6/9NIP in 33.33%,In 66.67%
visual acuity was between 6/12-6/18
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11. VISUAL ACUITY AT 8 WEEKS
TABLE-11
BCVA
SUB-GROUP-I
ORAL STEROIDS
SUB-GROUP-II
POST.SUB TENON
6/9PH6/6 8(58.33%) 8(66.67%)
6/12-6/18 2(16.67%) 3(25%)
<6/18 2(16.67%) 1(8.33%)
58.33% had BCVA of 6/6 at the end of 8 weeks in subgroup 1 and
66.67%  had 6/6 in subgroup 2. In 16.67% of subgroup1 and 8.33% of
subgroup 2 the visual acuity was persistently low <6/18
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12. MEDIA CLARITY (VITRITIS) AT 8 WEEKS
TABLE-12
MEDIA CLARITY
VITRITIS
SUB-GROUP-I
ORAL
SUB-GROUP-II
POST.SUB-TENON
CLEAR 7(58.33%) 8(66.66%)
I 3(25%) 3(25%)
II 2(16.67%) 1(8.33%)
III 0 0
In 58.33%  patient in the subgroup 1 media cleared at end of 8th
week in subgroup 2  66.66% had clear view at end of 8th week. 16.67% of
patient in subgroup 1 and 8.33% of patient in subgroup 2 were resistant to
steroids and started on immunosuppressants.
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13. FUNDUS FLUORESCEIN ANGIOGRAPHY AT 8TH WEEK
TABLE-13
FFA
SUB-
GROUP-I
ORAL
SUB-GROUPII
POST.SUB-
TENON
Vessel staining 2 (16.67%) 1 (8.33%)
Areas capillary non-perfusion 12 (100%) 12 (100%)
Sheathing 12 (100%) 12 (100%)
In FFA it was found that 16.67% in the subgroup 1and 8.33% in
subgroup 2 showed active disease.
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14. VISUAL ACUITY AT 16 WEEKS
TABLE-14
BCVA
SUB-GROUP-I
ORAL
SUB-GROUP-II
POST.SUB-TENON
6/9PH6/6 10(83.33%) 11(91.67%)
6/12-6/18 2(16.67%) 1(8.33%)
<6/18 0 0
The Best corrected Visual acuity improved to 6/6 in 83.33% of oral
steroids group and in subgroup treated with posterior sub-tenon 91.67%
had BCVA of 6/6 at the end of 16weeks.
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15. MEDIA CLARITY AT 16TH WEEK
TABLE-15
MEDIA CLARITY
(GRADE)
SUB-GROUP-I
ORAL
SUB-GROUP-II
POST.SUB-TENON
0 10 (83.33%) 11 (91.67%)
I 2 (16.67%) 1 (8.33%)
II 0 0
III 0 0
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PST
91.67% of patient with posterior sub tenon and 83.33% of patient
with oral steroids had clear media at end of 16 weeks .Only 8.33% in the
subgroup 2 and 16.67% in the subgroup 1 had minimal activity indicate
resolution of disease
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16. FUNDUS FLUORESCEIN ANGIOGRAPHY AT 16TH WEEK
TABLE-16
FFA
SUB-GROUP-I
ORAL
SUB-GROUP-II
POST.SUB-TENON
VESSEL STAINING 0 0
AREAS CAPILLARY
NON-PERFUSION 12(100%) 12(100%)
SHEATHING 12(100%) 12(100%)
All Patients in the two group  had capillary non-perfusion and
sheathing of vessels, no evidence of activity at the end of 16wks.
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17. POST INTERVENTIONAL COMPLICATIONS
TABLE-17
COMPLICATIONS ORAL POST.SUB-TENON
GLAUCOMA 0% 1(5.26%)
CATARACT 0% 0%
WEIGHT GAIN 9(47.37%) 0%
GASTRITIS 2((16.67%) 0%
WEIGHT GAIN was the predominant adverse effect(47.37%)
among the oral steroid group only 16.67% reported, Gastritis problem in
the oral steroid group.
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DISCUSSION AND RESULTS
In this study of  50 cases of retinal vasculitis it was found that 25
cases (50%) were due to Eales disease and 10 cases(20%) were secondary
to ocular disease and 15 cases (30%) were secondary to systemic disease.
Among the 50 cases studied 43(86%) were males and 7 (14%) were
females.
In our study all Eales patients were Male.In patients with systemic
disease 7 patient among the 15 were females and remaining 8 were
males.All 10 patients with ocular disease  were males.
This male predilection was supported by Elliot AJ:Thirty year
observation of patients with Eales disease,in his study 93% were Male.6
Out  of the 50 cases studied  20 cases (40%) were in the age group
of 31-40 yrs.18 cases(36%) in the age group of 21-30yrs.6 cases(12%) in
the age group of 41-50 yrs. 4(8%) were >50 yrs of age. 2(4%) in the age
group of 10-20yrs.
Majority of patients with Eales were in the age group of 30-40
yrs.In a study by Donders in 1958 the average age for men was 28 years
and for women it was 30 years.
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Among the 25 cases with Eales 15(60%) cases were bilateral ,10
cases(40%) were unilateral , of the 15 patient with systemic disease 10
cases were bilateral and 5 were unilateral. In patients with ocular disease
5 were bilateral and 5 were unilateral.
Duke Elder had reported that as a rule Eales disease would be
bilateral in 90% of the cases if they are observed over a period of atleast
5 years.1
Among the 25 patients with Eales, 15 patients had an acute onset,
remaining patients in Eales disease and those with systemic and Ocular
disease had insidious onset.
Blurring of vision was the predominant symptom in about 20 cases
(40%)
Sudden loss of vision in 15 cases (30%), floaters were noted in both
group.
Among the clinical signs in patients with Eales, sheathing  of
vessels  noted in 20 eyes(50%), 15 eye (37.5%) had vitreous hemorrhage
and neovascularisation was seen in 5 eyes(12.5%)
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Among the clinical sign in patients with vasculitis secondary to
systemic disease sheathing noted in 5 eyes (20%), vein occlusion in 16
eyes (64%),
4 eyes (16%) had tractional retinal detachment.
Sheathing with exudation and vitritis noted  in 13 eyes(86.66%) of
patients with vasculitis secondary to ocular disease and vein occlusion
noted in 2 eyes.(13.33%).
Visual acuity of 6/6-6/12 was noted in 20 eyes (50%) of patients
with Eales, 6/24-6/60 seen in 5 eyes(12.5%) of patients and 5/60-PL  seen
in 15 eyes(37.5%).
5 eyes (20%) of patient with vasculitis due to systemic disease had
visual acuity of  6/24-6/60, 20eyes(80%) had visual acuity of <5/60 .
5 eye (33.33%) of patients with vasculitis due to ocular disease had
visual acuity of 6/24-6/60, 10 eye (66.66%) of these patient had visual
acuity of <5/60.
Of the 25 cases of Eales, 5 cases had mantoux positivity. These
patient were referred to chest physician and one patient was stated on
Antitubercular treatment as advised and was excluded from sub-group
analysis.
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SUB-GROUP ANALYSIS
Management
24 cases of Eales patient were randomly divided into 2 subgroups
of 12 cases each,
Sub group1 subjected to oral prednisalone (1mg/kg/day)
Subgroup 2 subjected to posterior sub tenon triamcinalone
Visual acuity and media clarity of the two groups observed after 8th,
12th, 16th week.
At the end of 8 weeks
58.33% had BCVA of 6/6 in subgroup 1 and 66.67%  had 6/6 in
subgroup 2.In 16.67% of subgroup1 and 8.33% of subgroup 2 the visual
acuity was persistently low <6/18.
At the end of 8weeks
In 58.33%  patient in the subgroup 1and 66.66% in subgroup 2 had
clear view of the media.16.67% of  patient in subgroup 1 and 8.33% of
patient in subgroup 2 had grade II vitritis and were resistant to steroids
and started on immunosuppressants
The patients were reviewed at 12th and 16th week
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At the end of 16th week
The Best corrected Visual acuity improved to 6/6 in 83.33% of oral
steroids group(sub-group 1) and in subgroup 2( treated with posterior sub-
tenon) 91.67% had BCVA of 6/6. In 8.33% of subgroup2 and 16.67% in
the subgroup 1 had visual acuity of 6/12-6/18. The chi square test
showed a p=0.361, showed no significant difference in the efficiency of
the two subgroup. 91.67% of patient with posterior sub tenon and 83.33%
of patient with oral steroids had clear media at end of 16 weeks .Only
8.33% in the subgroup2 and 16.67% in the subgroup 1 had minimal
activity which indicate resolution of disease following treatment with
immunosuppressants.
15 eye of Eales patient with  vitreous hemorrhage were kept  under
observation and the hemorrhage was found to be resolving  during the
follow up period.
Complications
Oral steroids were associated with systemic complication of weight
gain in 9 out of  12 cases
Gastritis was observed in 2 out of 12 cases treated with oral
steroids. Posterior sub-tenon was associated with glaucoma in 1 of 12
cases
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CONCLUSION
Primary vasculitis is predominant (50%)among the vasculitis in our
study.
From our intervention it was clear that steroid in any mode of
administration was efficacious in controlling the inflammation in acute
disease .
2 patients (16.67%) in the oral steroid group and 1 patient (8.33%)
in posterior sub-tenon group required immunosuppressants.
No patients in our study required laser theraphy for
neovascularisation during the follow up period.
The final visual outcome in
Subgroup 1(ORAL STEROIDS) at end of 16 weeks was 6/6 in
83.33%,16.67%    had visual acuity of  6/12-6/18
Subgroup 2(POSTERIOR SUB-TENON) at the end of 8 weeks
was 6/6 in 91.67%, 8.33% had    visual acuity of 6/12-6/18.
No activity(grade-0 vitritis) was seen in 83.33% of cases  in the
subgroup 1 and 91.67% of subgroup 2.
Male predliction was noted in our study
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30-40yrs is the predominant age group affected in our study
Bilaterality was predominant among patient with Eales disease and
vasculitis due to Systemic disease.
In  patients with Primary vasculitis local steroid administered with
safety and skill is efficacious in controlling active disease with minimal
complication compared to systemic administration.
Although systemic steroids are equally efficacious in controlling
active disease and easily administered,  adverse  systemic complications
is a matter of concern.
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PROFORMA
NAME                                          AGE/SEX
OP.NO/IP.NO:                             DATE
ADDRESS
OCCUPATION
PRESENTING COMPLAINTS
Defective Vision
Distance/Near
Total Loss Of Vision
Floaters
Positive Scotoma
Micopsia/Macropsia/Metamorphopsia
Field Defect
Pain And Redness
OCULAR EXAMINATION
RE                      LE
Visual Acuity
Lids/Conjunctiva
Cornea
Anterior chamber
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Iris
Pupil
Lens
Vitreous
Tension
Retinoscopy                                              Subject
Myopia/hyperopia
Normal
Corrected vision
Fundus Examination
Direct Ophthalmoscopy
RE                       LE
Media
Disc
Vessels – Phlebitis peripheral
Central
Arteritis - Peripheral
Central
Combined  arteritis/phlebitis
Neovascularisation
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NVD -
NVE -
Indirect Ophthalmoscopy
Goldman 3 mirror
INVESTIGATION
Total count
Differential count
Peripheral smear
ESR
Bleeding time/Clotting time
Bloodsugar
Urinanalysis
VDRL and FTA-ABS
Tuberculin skin testing
TORCH Screening
Serum ACE
Rheumatoid factor
Antinuclear antibody
Antineutrophil cytoplasmic antibody
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Fundus fluorescein angiography
1.New vessels
2.Capillary non-perfusion
OTHER SPECIALITIES OPINION:
TREATMENT
Oral
Posterior Sub-Tenon
Laser
Pan-Retinal Photocoagulation
Vitrectomy.
FOLLOW-UP
4th week-
Visual acuity
Vitritis grade.
8th week
Visual acuity
Vitritis grade.
12th week
Visual acuity
Vitritis grade.
16th week
Visual acuity
Vitritis grade.
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KEY TO MASTER CHART
M - Male
F - Female
BE - Both eye
RE - Right eye
LE - Left eye
SYMPTOMS
LOV - Loss of vision
F - Floaters
DV - Defective vision
M.O.P-MODE OF  PRESENTATION
SO - Sudden onset
IO - Insidious onset
V.A - Visual Acuity
NIP - No improvement with pin hole
PL - Perception of light
HM - Hand movements
CFCF - Counting fingers close to face
C.O.R.V-CLASSIFICATION OF  RETINAL VASCULITIS
Primary
Secondary to systemic disease
Secondary to ocular disease
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CLINICAL SIGNS
S/V - Sheathing of vessels/vitritis
V.O - Vein of Occlusion
Neo - Neovascularization
T.R.D - Tractional Retinal Detachment
S/V/E - Sheathing of vessel/vitritis/ Exudation
MEDIA CLARITY
M.N.V - Media  no view
CL - Clear
NAME SEX AGE EYEAFFECTED M.O.P ONSET
SUB
GROUP
RE LE PRIMARY SYSTEMIC.D OCULAR.D S/V V.O NEO V.H T.R.D S/E/V RE LE RE LE RE LE RE LE RE LE VES.STAIN CNP NEO SHEATHING VES.STAIN CNP NEO SHEATHING GLAUCO CATRAC WT.GAIN GASTRITIS
KUMAR M 32 BE LOV SO HM 6/12NIP YES LE RE MNV I 1 1/60NIP 6/9PH6/6 MNV CL 4/6OPH6/60 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO YES NO
SASIKUMAR M 38 BE LOV/F SO 6/9NIP HM YES RE LE I MNV 1 6/9PH6/6 2/60NIP CL MNV 6/9PH6/6 3/60NIP CL III NO RE NO RE NO RE NO RE NO NO YES YES
ARUNKUMAR M 36 BE LOV/F SO 6/12NIP HM YES RE LE II MNV 2 6/9NIP 1/60NIP I MNV 6/9PH6/6 3/60PH6/60 CL III NO RE NO RE NO RE NO RE NO NO NO NO
SRINIVASAN M 31 BE LOV SO HM 6/12NIP YES LE RE MNV II 2 1/2/60NIP 6/9NIP MNV I 3/60PH6/60 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO NO NO
VIMALKUMAR M 47 BE DV IO 2/60NIP 3/60NIP AIDS BE CL CL
SRINIVASAN M 32 BE LOV/F SO 6/9NIP 1/2/60NIP YES RE LE I MNV 1 6/9NIP 2/60NIP I MNV 6/9PH6/6 4/60PH6/36 CL III NO RE NO RE NO RE NO RE NO NO YES NO
SAKTHIVEL M 31 BE LOV SO 6/18NIP HM YES RE LE II MNV 1 6/24NIP 2/60NIP III MNV 6/12NIP 2/60PH6/60 I III RE RE NO RE NO RE NO RE NO NO NO NO
PRIYA F 10 BE DV IO 3/60NIP 4/60PH6/60 SLE BE II II
KATHIKA F 15 BE DV IO 6/60NIP 6/60NIP SLE BE II II
SADAIYAPPAN M 42 RE DV IO 6/36PH6/24 6/24PH6/12 AIDS RE CL CL
KRISHNAMOORTHY M 27 BE LOV/F SO I/2/60NIP 6/9NIP YES LE RE MNV I 2 2/60NIP 6/9PH6/6 MNV CL 6/60NIP 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO NO NO
FRANCINA F 51 BE DV IO PL PL AIDS BE CL CL
POOJA F 30 BE DV IO 6/36NIP 6/36NIP APS II II
AMULRAJ M 40 BE LOV/F SO 6/12NIP HM YES RE LE I MNV 2 6/9PH6/6 1/60NIP CL MNV 6/9PH6/6 5/60PH6/60 CL III NO RE NO RE NO RE NO RE NO NO NO NO
RAJA M 40 BE LOV/F SO 6/18NIP CFCF YES RE LE II MNV 2 6/24NIP 2/6ONIP II MNV 6/12NIP 5/60PH6/60 I III RE RE NO RE NO RE NO RE YES NO NO NO
RAVUKUMAR M 52 BE DV IO PL PL AIDS BE CL CL
RAJESH M 40 BE LOV/F SO 1/60NIP 6/18NIP YES LE RE MNV II 1 2/60NIP 6/12NIP MNV I 4/60PH6/36 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO NO
RAMESH M 37 BE LOV/F SO 1/2/60NIP 6/9NIP YES LE RE MNV I 1 2/60NIP 6/9PH6/6 MNV CL 6/60NIP 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO NO
KASIAMMAL F 25 BE DV IO 1/60NIP 3/60NIP SLE BE II II
RAJENDRAN M 35 BE DV/F IO 4/60NIP HM BP BE III III
KUMAR M 48 LE DV/F IO 6/9NIP 4/60NIP AIDS LE CL CL
KILLIVALLAVAN M 27 BE DV/F IO 2/60NIP 2/60NIP BPAN BE III III
SURESH M 26 LE DV/F IO 6/9PH 6/6 6/12NIP YES LE CL II 1 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO NO NO
RAVI M 30 LE BV/F IO 6/9PH6/6 6/12NIP YES LE CL I 1 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO NO YES YES
LATHA F 25 BE DV IO 6/36NIP 6/60NIP SARCOID BE II III
SENTHIL M 39 BE LOV/F SO 6/18NIP HM YES RE LE II MNV 1 6/24NIP 2/60NIP II MNV 6/12NIP 6/60NIP I III RE RE NO RE NO RE NO RE NO NO YES NO
SHIVAKUMAR M 40 BE LOV/F SO CFCF 6/12NIP YES LE RE MNV II 2 2/60NIP 6/12NIP MNV I 6/60NIP 6/9PH6/6 III CL NO LE NO LE NO LE NO LE NO NO NO NO
RAMESH M 40 BE LOV/F SO 6/9NIP 1/2/60NIP YES RE LE I MNV 2 6/9PH6/6 2/60NIP CL MNV 6/9PH6/6 6/60PH 6/36 CL III NO RE NO RE NO RE NO RE NO NO YES NO
MURUGAN M 37 LE DV IO 6/12PH6/6 5/60NIP LP LE CL III
BABU M 35 RE DV IO 4/60NIP 6/12PH6/6 RP RE III CL
DEVI F 46 BE DV IO 1/2/60NIP 1/60NIP AIDS BE CL CL
SETHU M 27 RE BV/F IO 6/9NIP 6/9PH6/6 YES RE I CL 2 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO RE NO RE NO RE NO RE NO NO NO NO
RAJA M 21 LE BV/F IO 6/12PH6/6 6/12NIP YES LE CL I 2 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO NO NO NO
VINOTH M 28 BE DV/F IO 4/60NIP 4/60NIP BP BE III III
SURYA M 30 BE DV/F IO 3/60NIP 4/60NIP BP BE III III
MUTHUKUMAR M 43 LE DV IO 6/24PH6/6 6/36NIP AIDS LE CL CL
VELMURUGAN M 42 LE DV IO 6/18PH6/6 6/60NIP AIDS LE CL CL
VIJAY M 24 RE DV/F IO 4/60NIP 6/12PH6/6 RP RE III CL
VEERA M 26 LE DV/F IO 6/9PH6/6 3/60NIP LP LE CL III
RAJESHKRISHNA M 30 RE DV/F IO 4/60NIP 6/24NIP RP RE III I
MANIAJ M 51 BE DV IO 1/60NIP 2/60NIP AIDS BE CL CL
DHARSAN M 24 BE BV/F SO 6/9NIP HM YES RE LE I MNV
SATHYAMOORTHY M 27 BE DV/F IO 4/60NIP 3/60NIP BP III III
SENTHILMURUGAN M 30 LE BV/F IO 6/9PH 6/6 6/12NIP YES LE CL I 1 6/9PH6/6 6/9NIP CL CL 6/9PH6/6 69PH6/6 CL CL NO LE NO LE NO LE NO LE NO NO YES NO
BALAJI M 51 RE DV IO 5/60NIP 6/12NIP AIDS RE CL CL
SANTHOSH M 37 RE BV/F IO 6/12NIP 6/9PH6/6 YES RE I CL 2 6/12NIP 6/9PH6/6 I CL 6/9PH6/6 6/9PH6/6 CL CL NO RE NO RE NO RE NO RE NO YES NO NO
SUNDAR M 30 LE BV/F IO 6/9PH6/6 6/9NIP YES LE CL I 1 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO YES NO
KAESAVAN M 40 LE BV/F IO 6/9PH6/6 6/9NIP YES LE CL I 2 6/9PH6/6 6/12NIP CL I 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO NO NO NO
MADHAVAN M 38 RE BV/F IO 6/12NIP 6/9PH6/6 YES RE I CL 2 6/9PH6/6 6/9PH6/6 CL CL 6/9PH6/6 6/9PH6/6 CL CL NO RE NO RE NO RE NO RE NO NO NO NO
SHRIRAM M 40 LE BV/F IO 6/9PH6/6 6/12NIP YES LE CL II 1 6/9PH6/6 6/12NIP CL I 6/9PH6/6 6/9PH6/6 CL CL NO LE NO LE NO LE NO LE NO YES NO NO
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